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for Fosamax, Actonel, and Protelos, and from the European label
for Bonviva. Costs of fractures were taken from the NICE review
of Protelos and costs of the medications were taken from the
MIMS listing from February, 2007. Utilities were obtained from
the literature (Kanis, OI 2004;15:20–6). RESULTS: For patients
50 and older, zoledronic acid 5 mg dominated (i.e., more effective
at lower cost) branded Fosamax, Actonel, and Protelos. For
patients 70 and older, zoledronic acid 5 mg dominated Bonviva
while at lower ages, it was more cost effective (ICER < 3,100/
QALY gained). Incremental cost effectiveness ratios against
calcium plus vitamin D for zoledronic acid 5 mg were around or
below the usually referenced threshold of 20 K/QALY, ranging
from 20,582/QALY at age 50 to 7,418/QALY at age 80.
For the other treatments, the ranges of ICER versus calcium
plus vitamin D were 36,095/QALY to 12,542/QALY for
Fosamax, 53,916/QALY to 22,261/QALY for Actonel,
50,840/QALY to 26,179/QALY for Protelos, and 158,479/
QALY to 57,583/QALY for Bonviva. CONCLUSION: For
patients aged 50 and above with a BMD T-score of -2.5,
zoledronic acid 5 mg either dominates or is cost-effective com-
pared with Fosamax, Actonel, Protelos, and Bonviva.
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OBJECTIVES: The purpose of the study was to assess the cost-
effectiveness of the recombinant human PTH (1–34) (teri-
paratide) (Forsteo, Eli Lilly) and recombinant human PTH
(1–84) (Preotact, Nycomed) in subjects with similar clinical
characteristics to patients with osteoporosis in normal Swedish
clinical practice. METHODS: The cost-effectiveness was esti-
mated in an existing Markov cohort osteoporosis model using
6-month cycles and a lifetime horizon. The model was popu-
lated with Swedish epidemiological and economic data. To
reﬂect the normal clinical practice, the simulated subjects cor-
responded to the Swedish cohort in the European Forsteo
Observational Study (EFOS) (mean age 72 years, total hip
T-score -2.7, 3.5 prevalent vertebral fractures). The cost per
QALY gained of both teriparatide and PTH (1–84) was esti-
mated compared to no treatment based on efﬁcacy estimates
from phase III pivotal clinical trials of each drug. For teri-
paratide, the risk reduction for new vertebral fractures was
65% and for non-vertebral fragility fractures 53%, while PTH
(1–84) reduced the risk of vertebral fractures by 58% and
showed no difference in non-vertebral fracture risk reduction.
An indirect cost-effectiveness comparison between the two regi-
mens was also attempted. The annual drug cost of teriparatide
and PTH (1–84) in Sweden was €5241 and €4643, respectively.
Both treatment regimens were assumed to be given for 18
months per local reimbursement guidelines. The analysis took a
societal perspective excluding costs in added life years in the
base estimations. RESULTS: In the base case analysis excluding
the impact of hypercalcaemia the cost per QALY gained with
teriparatide and PTH (1–84) vs. no treatment was estimated at
€47,811 and €125,474, respectively. An indirect comparison
between the two treatments indicated teriparatide to be a domi-
nating alternative. CONCLUSION: This study suggests that,
based on the efﬁcacy estimates from pivotal clinical trials and
the Swedish cost of both drugs, teriparatide is a more cost-
effective treatment option than PTH (1–84).
POS10
COST-OF-ILLNESS STUDY OF HIP FRACTURE AMONG
KOREAN ELDERLY WOMEN: INCIDENCE-BASED APPROACH
Kang HY1, Park S2, Kang DR3, Kim JY4, Chang YH5, Choi WJ2,
Moon SH6,Yang KH6, Park JY7, Kwon SY8
1Yonsei University, Seoul, South Korea, South Korea, 2Health Insurance
Review Agency, Seoul, South Korea, 3Severance Hospital Clinical Trials
Center, Seoul, South Korea, 4Yonsei University, Seoul, South Korea,
5Department of Public Health, Graduate School,Yonsei University,
Seoul, South Korea, 6Department of Orthopedics, College of
Medicine,Yonsei University, Seoul, South Korea, 7Konkuk University,
Seoul, South Korea, 8The Catholic University of Korea, Seoul, South
Korea
OBJECTIVES: To estimate the economic burden of patients with
osteoporotic hip fracture amongKoreanwomen.METHODS:All
claims records of Korean National Health Insurance for women
50 years of age or older with a diagnosis of hip fracture from 2002
to 2004 were identiﬁed. The ﬁrst 6-month period was set to be a
‘window period,’ such that patients were deﬁned as incident cases
if their ﬁrst record of fracture visit or admissionwas observed after
June 30, 2002. We excluded patients with multiple fractures,
patients with the records of high-cost diseases, such as cancer, and
patients without a record of a diagnosis or prescription for
osteoporosis. For each patient, we cumulated the claims amount
of the ﬁrst fracture visit or admission and follow-up treatments for
2 years after the incidence of fracture. Also, to investigate out-of-
pocket costs outside the health care institutions, face-to-face
interviews were conducted with 101 patients from 4 general
hospitals who had experienced a hip fracture at least 6 months
before the time of the interview. The total cost for fracture was the
sum of the direct health care costs, transportation costs for visits
to hospitals, and caregivers’ time cost spent hospital or outpatient
visits. RESULTS: A total of 22,247 osteoporotic hip fracture
patients were identiﬁed during 2.5 years. For the ﬁrst year of
fracture, patients had an average of 3.28 visits and 0.97 admis-
sions, whereas 0.35 visits and 0.02 admissions were recorded for
the second year. The 2-year cost was US$8,538 and increased
exponentially with age, $7,616 for 50–64 years old, $9,542 for
65–74, $10,077 for 75–84, and $10,118 for 85 or above. CON-
CLUSION: Exploring the economic burden of osteoporotic hip
fracture will motivate policy makers and clinicians to adopt
effective treatment options for osteoporosis to prevent the inci-
dence of fracture among elderly population.
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OBJECTIVES: To estimate hospital and facility costs resulting
from falls in long term care facilities (LTCFs). METHODS: The
study employed a non-randomized, before and after with com-
parison group design. Propensity scoring and matching were
used to control for baseline differences between fallers and non-
fallers. A multi-facility long-term care company provided data
from residents institutionalized between January 1, 2002 and
October 30, 2004. Data included Minimum Data Set (MDS)
observations, Resource Utilization Group (RUG) classiﬁcations,
and demographics. An index date was assigned to each resident
to identify pre-and post-periods. The index date was deﬁned as
the date of the ﬁrst fall for fallers. The index date was assigned to
non-fallers such that the time in the pre-period was equal for
fallers and non-fallers. Hospital costs were estimated from MDS
measures of the numbers of hospitalizations in each period and a
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mean fall-related hospital reimbursement of $14,769. LTCF costs
were estimated from RUG classiﬁcations and associated payment
rates. Total reimbursement per resident per year (PRPY) was
calculated as the sum of annualized LTCF and hospital reimburse-
ment. Fall-related costswere estimated as the difference in changes
in reimbursement between groups from pre- to post-periods.
RESULTS: The matched sample included 1130 fallers and 1130
non-fallers. Fallers had substantially more fractures and hospital-
izations in the post-period than non-fallers. The sum of LTCF and
hospital costs increased $4722 PRPY for fallers from pre- to
post-periods; non-fallers’ costs decreased by $1,537 PRPY. The
difference in changes—$6,259 (95% CI = $2,034 to $10,484)
PRPY—represents fall-related costs. About 60% of the difference
was attributable to higher hospitalization costs for fallers. In,
addition fallers weremore likely to be discharged to hospitals or to
die. CONCLUSION: Falls in LTCFs result in substantial costs,
primarily due to higher rates of fractures and hospitalizations.
OSTEOPOROSIS—Health Care Use & Policy Studies
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OBJECTIVES: To estimate the proportion of patients who
receive pharmacologic treatment for osteoporosis following an
osteoporotic fracture and to identify factors that determine
which patients receive treatment. METHODS: Data were taken
from the Medical Expenditures Panel Survey (MEPS) for 2001–
2003. Women who reported a wrist, vertebral, or hip fracture
after the age of 50 years were identiﬁed. Prescription data were
assessed for these subjects and two groups were identiﬁed: those
who received pharmacologic treatment following a fracture and
those who did not. Using Andersen’s Behavioral Model of Health
Services Utilization, two categories of variables were examined
to determine factors related to treatment: characteristics of the
health delivery system and characteristics of the population at
risk. RESULTS: The ﬁnal sample consisted of 129 subjects. This
represented an estimated 1,238,086 women with a history of
osteoporotic fracture during 2001 to 2003 in the civilian, female,
non-institutionalized U.S. population. Of these, 38% received
treatment. Those treated were most likely to receive either
hormone therapy or bisphosphonates. The only variable that was
signiﬁcantly different (p < 0.05) between those treated and not
treated was type of insurance coverage; patients covered by a
private HMO were more likely to receive pharmacologic treat-
ment. CONCLUSION: Most women do not receive pharmaco-
logic treatment for osteoporosis following a fracture. Substantial
efforts should be made to close the gap between guideline rec-
ommendations and clinical practice. We were unable to identify
variables other than insurance coverage that were related to
treatment.
OSTEOPOROSIS—Methods and Concepts
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OBJECTIVES: Determination of medication persistence, using
administrative pharmacy data, relies on the pharmacist-reported
days supply and an allowable gap between prescriptions. This
concept is used consistently in secondary research, but there are no
standards on the appropriate gap to allow between the run-out of
the days supply of one prescription and the dispensed date of the
patient’s subsequent prescription. The purpose of this research is
to evaluate the impact of varying the allowable gapwhen assessing
persistence in a market with variable dosing frequencies.
METHODS: The osteoporosis market includes competing bis-
phosphonate products with different dosing regimens—weekly or
monthly doses.We assessed the impact of expanding the allowable
gap on persistence and evaluated the impact of allowing different
gaps for each product because differences in dosing frequencies
may impact patients’ reﬁll patterns. Finally, we examined the reﬁll
patterns of patients on each product and the potential impact of
those patterns on the determination of persistence. Cox propor-
tional hazards models, adjusted for patient characteristics, were
used to compare persistence between products. We used the IMS
Longitudinal Prescription (LRx) database, consisting of anony-
mized patient retail prescription records in the U.S. The study
cohort included 165,955 women aged 50 years or older who
initiated therapy between September and November 2005.
RESULTS:As the allowable gap increased, the average persistence
of newly treated bisphosphonate patients also increased (112 days
using 30-day gap, 125 days using 45-day gap), but relative differ-
ences between products were similar, with monthly patients less
persistent than weekly (HR = 1.09 95%CI = (1.08,1.10) using
30-day gap; HR = 1.05 95%CI = (1.03,1.06) using 45-day gap).
When the gap was allowed to differ across products (45-day gap
for monthly vs. 30-day gap for weekly), a different relationship
between products was found (HR = 0.97 95%CI = (0.96,0.98))
CONCLUSION: It is important to consider the allowable gap, in
relation to dosing frequencies, when interpreting results from
persistence measures.
OSTEOPOROSIS—Patient Reported Outcomes
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OBJECTIVES: To compare SF-6D and EQ-5D in both, absolute
values and sensitivity to change over time, in osteoporotic hip
fracture patients in Poland. METHODS: Data were extracted
from prospective study on outcomes of osteoporotic hip fractures
in Poland (PolHipQol study). Eligible patients had to be 60 years
or more, have low energy femoral neck fracture or pertrochant-
eric fracture of the femur, absence of severe cognitive dysfunction
(measured by Hodkinson’s Abbreviated Mental Test Score) and
both SF-36 and EQ-5D post fracture measurements avaiable.
SF-36 scores were translated into SF-6D utilities using the algo-
rithm developed by Brazier et al. The EQ-5D utilities were based
on the European VAS value set. The correlations between pref-
erence measures were assessed using Spearman’s rank correlation
coefﬁcient. Sensitivity to change over one year was evaluated
with the standardized response mean (SRM). RESULTS: Post
fracture data of 65 patients (mean age 77.8; 54 women) and one
year follow-up data of 51 patients were avaiable (9 patients were
ceased and 5 lost to follow-up). Mean SF-6D utility decreased
from 0.65 (SD 0.13) before fracture (recall method) to 0.49
(0.10) after fracture, and then increased to 0.55 (0.12) at the ﬁnal
follow-up. Mean EQ-5D utility decreased from 0.73 (0.22)
before fracture to 0.24 (0.17) after fracture, and then increased
to 0.47 (0.23) at the ﬁnal follow-up. SF-6D and EQ-5D utilities
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